GenCore version 5.1.4_p5_4578


OM protein - protein search, using sw model

Run on: March 11, 2003, 23:09:45 ; Search time 53 Seconds
(without alignments)
2516.677 Million cell updates/sec

Title: US-10-046-433-40
Perfect score: 5506
Sequence: 1 MAEPGHSHHLSARVRGRTER.....LGRSNHLPPRGLLMDLTQCR 1001

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 908470 seqs, 133250620 residues

Total number of hits satisfying chosen parameters: 908470

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : A_Geneseq_101002:*
1: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1980.DAT:*
2: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1981.DAT:*
3: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1982.DAT:*
4: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1983.DAT:*
5: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1984.DAT:*
6: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1985.DAT:*
7: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1986.DAT:*
8: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1987.DAT:*
9: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1988.DAT:*
10: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1989.DAT:*
11: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1990.DAT:*
12: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1991.DAT:*
13: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1992.DAT:*
14: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1993.DAT:*
15: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1994.DAT:*
16: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1995.DAT:*
17: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1996.DAT:*
18: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1997.DAT:*
19: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1998.DAT:*
20: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1999.DAT:*
21: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA2000.DAT:*
22: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA2001.DAT:*
23: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA2002.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

| Result No. | Score | % Query Match | Length | DB | ID | Description |
|---|---|---|---|---|---|---|
| 1 | 5506 | 100.0 | 1001 | 22 | AAB35333 | Human TR13 recepto |
| 2 | 5376 | 97.6 | 1013 | 21 | AAB26179 | Human CASB619 prot |
| 3 | 5363 | 97.4 | 1013 | 22 | AAB83845 | Amino acid sequenc |
| 4 | 5341 | 97.0 | 1013 | 22 | AAU12190 | Human PRO4985 poly |
| 5 | 5005 | 90.9 | 911 | 22 | AAB83850 | Amino acid sequenc |
| 6 | 4784 | 86.9 | 870 | 22 | AAB83851 | Amino acid sequenc |
| 7 | 3870 | 70.3 | 750 | 22 | AAB35328 | Human TR13 recepto |
| 8 | 2982.5 | 54.2 | 1027 | 22 | AAB70256 | TR16-long receptor |
| 9 | 2815.5 | 51.1 | 963 | 22 | AAB70255 | TR16-short recepto |
| 10 | 2491 | 45.2 | 495 | 20 | AAY59972 | Human endometrium |
| 11 | 2119 | 38.5 | 383 | 22 | AAB83853 | Amino acid sequenc |
| 12 | 1761.5 | 32.0 | 372 | 22 | AAB85768 | Human seven-transm |
| 13 | 1448 | 26.3 | 464 | 22 | AAB48377 | Human SEC10 protei |
| 14 | 1307.5 | 23.7 | 411 | 22 | AAB48372 | Human SEC5 protein |
| 15 | 1169 | 21.2 | 209 | 22 | AAB83852 | Amino acid sequenc |
| 16 | 889.5 | 16.2 | 208 | 21 | AAB53442 | Human colon cancer |
| 17 | 776 | 14.1 | 147 | 22 | AAB83849 | Peptide fragment o |
| 18 | 710 | 12.9 | 150 | 20 | AAY12274 | Human 5' EST secre |
| 19 | 518 | 9.4 | 105 | 21 | AAB26180 | Human CASB619 prot |
| 20 | 325 | 5.9 | 56 | 22 | AAB83847 | Peptide fragment o |
| 21 | 284 | 5.2 | 74 | 22 | AAB70281 | Peptide #25. Unid |
| 22 | 273 | 5.0 | 81 | 22 | ABB39918 | Peptide #7424 enco |
| 23 | 273 | 5.0 | 81 | 22 | ABB24471 | Protein #6470 enco |
| 24 | 273 | 5.0 | 81 | 22 | AAM60663 | Human brain expres |
| 25 | 273 | 5.0 | 81 | 22 | AAM73335 | Human bone marrow |
| 26 | 273 | 5.0 | 81 | 22 | AAM33535 | Peptide #7572 enco |
| 27 | 273 | 5.0 | 81 | 23 | ABG43186 | Human peptide enco |
| 28 | 269 | 4.9 | 52 | 22 | AAB83848 | Peptide fragment o |
| 29 | 252 | 4.6 | 1576 | 21 | AAB19802 | Human laminin 2 ma |
| 30 | 252 | 4.6 | 1576 | 21 | AAB48453 | Human laminin 8 po |
| 31 | 252 | 4.6 | 1576 | 23 | ABB81595 | Human laminin 10 t |
| 32 | 252 | 4.6 | 1584 | 21 | AAB19804 | Human laminin 2 ga |
| 33 | 252 | 4.6 | 1609 | 21 | AAB19801 | Human laminin 2 ga |
| 34 | 252 | 4.6 | 1609 | 21 | AAB48452 | Human laminin 8 po |
| 35 | 252 | 4.6 | 1609 | 23 | ABB81594 | Human laminin 10 t |
| 36 | 252 | 4.6 | 1617 | 21 | AAB19803 | Human laminin 2 ga |
| 37 | 251 | 4.6 | 1609 | 19 | AAW50898 | Human laminin G1 c |
| 38 | 244 | 4.4 | 45 | 22 | AAB83846 | Peptide fragment o |
| 39 | 233 | 4.2 | 3594 | 23 | AAE20147 | Mouse C3b/C4b comp |
| 40 | 229.5 | 4.2 | 1572 | 21 | AAB19806 | Mouse laminin 2 ma |
| 41 | 229.5 | 4.2 | 1572 | 21 | AAB48455 | Mouse laminin 8 po |
| 42 | 229.5 | 4.2 | 1572 | 23 | ABB81597 | Mouse laminin 10 t |
| 43 | 229.5 | 4.2 | 1605 | 21 | AAB19805 | Mouse laminin 2 ga |
| 44 | 229.5 | 4.2 | 1605 | 21 | AAB48454 | Mouse laminin 8 po |
| 45 | 229.5 | 4.2 | 1605 | 23 | ABB81596 | Mouse laminin 10 t |

ALIGNMENTS

RESULT 1
AAB35333
ID AAB35333 standard; Protein; 1001 AA.
XX
AC AAB35333;
XX
DT 08-MAY-2001 (first entry)
XX
DE Human TR13 receptor protein SEQ ID NO: 40.
XX
KW Human; tumour necrosis factor receptor; TR13; TR14; infection;
KW cancer; autoimmune disease; allergy; inflammatory disease;
KW graft rejection; apoptosis; cardiovascular disease; aneurysm.
XX
OS Homo sapiens.
XX
PN WO200105834-A1.
XX
PD 25-JAN-2001.
XX
PF 14-JUL-2000; 2000WO-US19343.
XX
PR 16-JUL-1999; 99US-0144087.
PR 18-AUG-1999; 99US-0149450.
PR 20-AUG-1999; 99US-0149712.
PR 10-SEP-1999; 99US-0153089.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Ruben SM, Ni J, Young PE;
XX
DR WPI; 2001-112682/12.
XX

PT Nucleic acids encoding 2 human tumor necrosis factor receptor
PT polypeptides ((TR13) and (TR14)), useful for the prevention, diagnosis
PT and treatment of, e.g. cancers, acquired immune deficiency syndrome and
PT hypohidrotic ectodermal dysplasia -
XX
PS Claim 40; Page 398-401; 418pp; English.
XX
CC The present invention provides the protein and coding sequences of the
CC human tumour necrosis factor receptors TR13 and TR14. These sequences are
CC useful in the diagnosis and treatment of many diseases, including cancer,
CC autoimmune diseases, cardiovascular disorders, allergies,
CC neurodegenerative diseases, graft rejection, inflammation, aneurysms and
CC infections.
XX
SQ Sequence 1001 AA;

Query Match 100.0%; Score 5506; DB 22; Length 1001;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1001; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy      1 MAEPGHSHHLSARVRGRTERRIPRLWRLLLWAGTAFQVTQGTGPELHACKESEYHYEYTA 60
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1 MAEPGHSHHLSARVRGRTERRIPRLWRLLLWAGTAFQVTQGTGPELHACKESEYHYEYTA 60

Qy     61 CDSTGSRWRVAVPHTPGLCTSLPDPVKGTECSFSCNAGEFLDMKDQSCKPCAEGRYSLGT 120
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     61 CDSTGSRWRVAVPHTPGLCTSLPDPVKGTECSFSCNAGEFLDMKDQSCKPCAEGRYSLGT 120

Qy    121 GIRFDEWDELPHGFASLSANMELDDSAAESTGNCTSSKWVPRGDYIAFNTDECTATLMYA 180
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    121 GIRFDEWDELPHGFASLSANMELDDSAAESTGNCTSSKWVPRGDYIAFNTDECTATLMYA 180

Qy    181 VNLKQSGTVNFEYYYPDSSIIFEFFVQNDQCQPNADDSRWMKTTEKGWEFHSVELNRGNN 240
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    181 VNLKQSGTVNFEYYYPDSSIIFEFFVQNDQCQPNADDSRWMKTTEKGWEFHSVELNRGNN 240

Qy    241 VLYWRTTAFSVWTKVPKPVLVRNIAITGVAYTSECFPCKPGTYADKQGSSFCKLCPANSY 300
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    241 VLYWRTTAFSVWTKVPKPVLVRNIAITGVAYTSECFPCKPGTYADKQGSSFCKLCPANSY 300

Qy    301 SNKGETSCHQCDPDKYSEKGSSSCNVRPACTDKDYFYTHTACDANGETQLMYKWAKPKIC 360
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    301 SNKGETSCHQCDPDKYSEKGSSSCNVRPACTDKDYFYTHTACDANGETQLMYKWAKPKIC 360

Qy    361 SEDLEGAVKLPASGVKTHCPPCNPGFFKTNNSTCQPCPYGSYSNGSDCTRCPAGTEPAVG 420
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    361 SEDLEGAVKLPASGVKTHCPPCNPGFFKTNNSTCQPCPYGSYSNGSDCTRCPAGTEPAVG 420

Qy    421 FEYKWWNTLPTNMETTVLSGINFEYKGMTGWEVAGDHIYTAAGASDNDFMILTLVVPGFR 480
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    421 FEYKWWNTLPTNMETTVLSGINFEYKGMTGWEVAGDHIYTAAGASDNDFMILTLVVPGFR 480

Qy    481 PPQSVMADTENKEVARITFVFETLCSVNCELYFMVGVNSRTNTPVETWKGSKGKQSYTYI 540
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    481 PPQSVMADTENKEVARITFVFETLCSVNCELYFMVGVNSRTNTPVETWKGSKGKQSYTYI 540

Qy    541 IEENTTTSFTWAFQRTTFHEASRKYTNDVAKIYSINVTNVMNGVASYCRPCALEASDVGS 600
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    541 IEENTTTSFTWAFQRTTFHEASRKYTNDVAKIYSINVTNVMNGVASYCRPCALEASDVGS 600

Qy    601 SCTSCPAGYYIDRDSGTCHSCPPNTILKAHQPYGVQACVPCGPGTKNNKIHSLCYNDCTF 660
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    601 SCTSCPAGYYIDRDSGTCHSCPPNTILKAHQPYGVQACVPCGPGTKNNKIHSLCYNDCTF 660

Qy    661 SRNTPTRTFNYNFSALANTVTLAGGPSFTSKGLKYFHHFTLSLCGNQGRKMSVCTDNVTD 720
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    661 SRNTPTRTFNYNFSALANTVTLAGGPSFTSKGLKYFHHFTLSLCGNQGRKMSVCTDNVTD 720

Qy    721 LRIPEGESGFSKSITAYVCQAVIIPPEVTGYKAGVSSQPVSLADRLIGVTTDMTLDGITS 780
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    721 LRIPEGESGFSKSITAYVCQAVIIPPEVTGYKAGVSSQPVSLADRLIGVTTDMTLDGITS 780

Qy    781 PAELFHLESLGIPDVIFFYRSNDVTQSCSSGRSTTIRVRCSPQKTVPGSLLLPGTCSDGT 840
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    781 PAELFHLESLGIPDVIFFYRSNDVTQSCSSGRSTTIRVRCSPQKTVPGSLLLPGTCSDGT 840

Qy    841 CDGCNFHFLWESAAACPLCSVADYHAIVSSCVAGIQKTTYVWREPKLCSGGISLPEQRVT 900
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    841 CDGCNFHFLWESAAACPLCSVADYHAIVSSCVAGIQKTTYVWREPKLCSGGISLPEQRVT 900

Qy    901 ICKTIDFWLKVGISAGTCTAILLTVLTCYFWKKNQKLEYKYSKLVMNATLKDCDLPAADS 960
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    901 ICKTIDFWLKVGISAGTCTAILLTVLTCYFWKKNQKLEYKYSKLVMNATLKDCDLPAADS 960

Qy    961 CAIMEGEDVEDDLIFTSKNHSLGRSNHLPPRGLLMDLTQCR 1001
          |||||||||||||||||||||||||||||||||||||||||
Db    961 CAIMEGEDVEDDLIFTSKNHSLGRSNHLPPRGLLMDLTQCR 1001
```

RESULT 2
AAB26179
ID AAB26179 standard; Protein; 1013 AA.
XX
AC AAB26179;
XX
DT 12-FEB-2001 (first entry)
XX
DE Human CASB619 protein #1.
XX
KW Human; CASB619; cancer; autoimmune disease; immunogen; vaccine;
KW epitope.
XX
OS Homo sapiens.
XX
PN WO200058460-A2.
XX
PD 05-OCT-2000.
XX
PF 20-MAR-2000; 2000WO-EP02478.
XX
PR 26-MAR-1999; 99GB-0007113.
PR 25-SEP-1999; 99GB-0022858.
XX
PA (SMIK ) SMITHKLINE BEECHAM BIOLOGICALS.
XX
PI Bruck CEM, Cassart J, Coche T, Vinals De Bassols YC;
XX
DR WPI; 2000-664923/64.
DR N-PSDB; AAA95442.
XX
PT Novel CASB619 polypeptides useful for diagnosing, and as vaccines for
PT prophylactic and therapeutic treatment of, cancers, particularly
PT ovarian and colon carcinoma, and autoimmune diseases -
XX
PS Claim 4; Page 54-56; 68pp; English.
XX
CC The present sequence comprises the human CASB619 protein sequence. This
CC protein is thought to be specifically or over-expressed in tumour cells,
CC and so can be used as a target for antigen-specific immune responses
CC which can cause destruction of the tumour cell. In addition, the protein
CC and gene can be used in cancer diagnosis, in the treatment of autoimmune
CC diseases and in vaccines against cancer and autoimmune disease. The
CC invention provides a number of epitopes derived from the protein which
CC can be used as immunogens.
XX
SQ Sequence 1013 AA;

Query Match 97.6%; Score 5376; DB 21; Length 1013;
Best Local Similarity 99.4%; Pred. No. 0;
Matches 978; Conservative 1; Mismatches 5; Indels 0; Gaps 0;

```
Qy      1 MAEPGHSHHLSARVRGRTERRIPRLWRLLLWAGTAFQVTQGTGPELHACKESEYHYEYTA 60
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1 MAEPGHSHHLSARVRGRTERRIPRLWRLLLWAGTAFQVTQGTGPELHACKESEYHYEYTA 60

Qy     61 CDSTGSRWRVAVPHTPGLCTSLPDPVKGTECSFSCNAGEFLDMKDQSCKPCAEGRYSLGT 120
```

```
                 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      61 CDSTGSRWRVAVPHTPGLCTSLPDPVKGTECSFSCNAGEFLDMKDQSCKPCAEGRYSLGT 120

Qy     121 GIRFDEWDELPHGFASLSANMELDDSAAESTGNCTSSKWVPRGDYIAFNTDECTATLMYA 180
                 ||||||||||||||||||||||||||||||||||||||||||||||| ||||||||||||
Db     121 GIRFDEWDELPHGFASLSANMELDDSAAESTGNCTSSKWVPRGDYIASNTDECTATLMYA 180

Qy     181 VNLKQSGTVNFEYYYPDSSIIFEFFVQNDQCQPNADDSRWMKTTEKGWEFHSVELNRGNN 240
                 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     181 VNLKQSGTVNFEYYYPDSSIIFEFFVQNDQCQPNADDSRWMKTTEKGWEFHSVELNRGNN 240

Qy     241 VLYWRTTAFSVWTKVPKPVLVRNIAITGVAYTSECFPCKPGTYADKQGSSFCKLCPANSY 300
                 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     241 VLYWRTTAFSVWTKVPKPVLVRNIAITGVAYTSECFPCKPGTYADKQGSSFCKLCPANSY 300

Qy     301 SNKGETSCHQCDPDKYSEKGSSSCNVRPACTDKDYFYTHTACDANGETQLMYKWAKPKIC 360
                 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     301 SNKGETSCHQCDPDKYSEKGSSSCNVRPACTDKDYFYTHTACDANGETQLMYKWAKPKIC 360

Qy     361 SEDLEGAVKLPASGVKTHCPPCNPGFFKTNNSTCQPCPYGSYSNGSDCTRCPAGTEPAVG 420
                 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     361 SEDLEGAVKLPASGVKTHCPPCNPGFFKTNNSTCQPCPYGSYSNGSDCTRCPAGTEPAVG 420

Qy     421 FEYKWWNTLPTNMETTVLSGINFEYKGMTGWEVAGDHIYTAAGASDNDFMILTLVVPGFR 480
                 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     421 FEYKWWNTLPTNMETTVLSGINFEYKGMTGWEVAGDHIYTAAGASDNDFMILTLVVPGFR 480

Qy     481 PPQSVMADTENKEVARITFVFETLCSVNCELYFMVGVNSRTNTPVETWKGSKGKQSYTYI 540
                 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     481 PPQSVMADTENKEVARITFVFETLCSVNCELYFMVGVNSRTNTPVETWKGSKGKQSYTYI 540

Qy     541 IEENTTTSFTWAFQRTTFHEASRKYTNDVAKIYSINVTNVMNGVASYCRPCALEASDVGS 600
                 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     541 IEENTTTSFTWAFQRTTFHEASRKYTNDVAKIYSINVTNVMNGVASYCRPCALEASDVGS 600

Qy     601 SCTSCPAGYYIDRDSGTCHSCPPNTILKAHQPYGVQACVPCGPGTKNNKIHSLCYNDCTF 660
                 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     601 SCTSCPAGYYIDRDSGTCHSCPPNTILKAHQPYGVQACVPCGPGTKNNKIHSLCYNDCTF 660

Qy     661 SRNTPTRTFNYNFSALANTVTLAGGPSFTSKGLKYFHHFTLSLCGNQGRKMSVCTDNVTD 720
                 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     661 SRNTPTRTFNYNFSALANTVTLAGGPSFTSKGLKYFHHFTLSLCGNQGRKMSVCTDNVTD 720

Qy     721 LRIPEGESGFSKSITAYVCQAVIIPPEVTGYKAGVSSQPVSLADRLIGVTTDMTLDGITS 780
                 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     721 LRIPEGESGFSKSITAYVCQAVIIPPEVTGYKAGVSSQPVSLADRLIGVTTDMTLDGITS 780

Qy     781 PAELFHLESLGIPDVIFFYRSNDVTQSCSSGRSTTIRVRCSPQKTVPGSLLLPGTCSDGT 840
                 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     781 PAELFHLESLGIPDVIFFYRSNDVTQSCSSGRSTTIRVRCSPQKTVPGSLLLPGTCSDGT 840

Qy     841 CDGCNFHFLWESAAACPLCSVADYHAIVSSCVAGIQKTTYVWREPKLCSGGISLPEQRVT 900
                 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     841 CDGCNFHFLWESAAACPLCSVADYHAIVSSCVAGIQKTTYVWREPKLCSGGISLPEQRVT 900

Qy     901 ICKTIDFWLKVGISAGTCTAILLTVLTCYFWKKNQKLEYKYSKLVMNATLKDCDLPAADS 960
                 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     901 ICKTIDFWLKVGISAGTCTAILLTVLTCYFWKKNQKLEYKYSKLVMNATLKDCDLPAADS 960

Qy     961 CAIMEGEDVEDDLIFTSKNHSLGR 984
                 ||||||||||||||||||  |:
Db     961 CAIMEGEDVEDDLIFTSKKSLFGK 984


RESULT 3
AAB83845
ID   AAB83845 standard; Protein; 1013 AA.
XX
AC   AAB83845;
XX
DT   23-JUL-2001  (first entry)
XX
DE   Amino acid sequence of a human protein expressed in tumour cells.
XX
KW   Tumour cell; immunological disease; autoimmune disease; cancer;
KW   infection.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Peptide         1..41
FT                   /note= "signal peptide"
FT   Domain          42..911
FT                   /note= "extracellular domain"
FT   Domain          912..930
FT                   /note= "transmembrane domain"
FT   Domain          931..1013
FT                   /note= "transmembrane domain"
XX
PN   WO200131003-A1.
XX
PD   03-MAY-2001.
XX
PF   30-OCT-2000; 2000WO-FR03032.
XX
PR   29-OCT-1999;   99FR-0013629.
XX
PA   (FABR ) FABRE MEDICAMENT SA PIERRE.
XX
PI   Delneste Y,  Magistrelli G,  Jeannin P,  Bonnefoy J;
XX
DR   WPI; 2001-328651/34.
DR   N-PSDB; AAF89765.
XX
PT   New nucleic acid, expressed in tumours and lymphoid tissue is useful for
PT   identifying agents for treating tumours and autoimmune disease  -
XX
PS   Claim 9; Page 48-51; 85pp; French.
XX
CC   The present sequence represents a human protein expressed in tumour
CC   cells. The polynucleotide is useful for screening cDNA/genomic DNA banks
CC   and for cloning isolated DNA; identifying mutant forms of the gene that
CC   encodes a human protein, where the mutations are associated with
CC   abnormal gene expression, or promoters and regulators of the gene,
CC   particularly for diagnosis; for recombinant expression of the derived
CC   protein; as probes and primers for detection and amplification; and
CC   as antisense therapeutics. The tumour expressed protein is useful for
CC   raising specific antibodies and to screen agents that modulate its
CC   activity, bind to it or interact with it. These agents are potentially
CC   useful for treatment or prevention of diseases associated with abnormal
CC   expression/activity of the protein, particularly immunological diseases
CC   (autoimmune diseases and cancer) or viral, bacterial, fungal or parasitic
CC   infections.
XX
SQ   Sequence   1013 AA;

  Query Match             97.4%;  Score 5363;  DB 22;  Length 1013;
  Best Local Similarity   99.2%;  Pred. No. 0;
  Matches  976;  Conservative    1;  Mismatches    7;  Indels    0;  Gaps    0;

Qy       1 MAEPGHSHHLSARVRGRTERRIPRLWRLLLWAGTAFQVTQGTGPELHACKESEYHYEYTA 60
                 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1 MAEPGHSHHLSARVRGRTERRIPRLWRLLLWAGTAFQVTQGTGPELHACKESEYHYEYTA 60

Qy      61 CDSTGSRWRVAVPHTPGLCTSLPDPVKGTECSFSCNAGEFLDMKDQSCKPCAEGRYSLGT 120
                 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      61 CDSTGSRWRVAVPHTPGLCTSLPDPVKGTECSFSCNAGEFLDMKDQSCKPCAEGRYSLGT 120

Qy     121 GIRFDEWDELPHGFASLSANMELDDSAAESTGNCTSSKWVPRGDYIAFNTDECTATLMYA 180
                 ||||||||||||||||||||||||||||||||||||||||||||||| ||||||||||||
Db     121 GIRFDEWDELPHGFASLSANMELDDSAAESTGNCTSSKWVPRGDYIASNTDECTATLMYA 180

Qy     181 VNLKQSGTVNFEYYYPDSSIIFEFFVQNDQCQPNADDSRWMKTTEKGWEFHSVELNRGNN 240
                 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     181 VNLKQSGTVNFEYYYPDSSIIFEFFVQNDQCQPNADDSRWMKTTEKGWEFHSVELNRGNN 240
```

```
Qy     241 VLYWRTTAFSVWTKVPKPVLVRNIAITGVAYTSECFPCKPGTYADKQGSSFCKLCPANSY 300
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     241 VLYWRTTAFSVWTKVPKPVLVRNIAITGVAYTSECFPCKPGTYADKQGSSFCKLCPANSY 300

Qy     301 SNKGETSCHQCDPDKYSEKGSSSCNVRPACTDKDYFYTHTACDANGETQLMYKWAKPKIC 360
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     301 SNKGETSCHQCDPDKYSEKGSSSCNVRPACTDKDYFYTHTACDANGETQLMYKWAKPKIC 360

Qy     361 SEDLEGAVKLPASGVKTHCPPCNPGFFKTNNSTCQPCPYGSYSNGSDCTRCPAGTEPAVG 420
           |||||||||||||||||||||||||||||||||| ||||||||||||||||||||||||||
Db     361 SEDLEGAVKLPASGVKTHCPPCNPGFFKTNNSTCQPCPYGPYSNGSDCTRCPAGTEPAVG 420

Qy     421 FEYKWWNTLPTNMETTVLSGINFEYKGMTGWEVAGDHIYTAAGASDNDFMILTLVVPGFR 480
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     421 FEYKWWNTLPTNMETTVLSGINFEYKGMTGWEVAGDHIYTAAGASDNDFMILTLVVPGFR 480

Qy     481 PPQSVMADTENKEVARITFVFETLCSVNCELYFMVGVNSRTNTPVETWKGSKGKQSYTYI 540
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     481 PPQSVMADTENKEVARITFVFETLCSVNCELYFMVGVNSRTNTPVETWKGSKGKQSYTYI 540

Qy     541 IEENTTTSFTWAFQRTTFHEASRKYTNDVAKIYSINVTNVMNGVASYCRPCALEASDVGS 600
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     541 IEENTTTSFTWAFQRTTFHEASRKYTNDVAKIYSINVTNVMNGVASYCRPCALEASDVGS 600

Qy     601 SCTSCPAGYYIDRDSGTCHSCPPNTILKAHQPYGVQACVPCGPGTKNNKIHSLCYNDCTF 660
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     601 SCTSCPAGYYIDRDSGTCHSCPPNTILKAHQPYGVQACVPCGPGTKNNKIHSLCYNDCTF 660

Qy     661 SRNTPTRTFNYNFSALANTVTLAGGPSFTSKGLKYFHHFTLSLCGNQGRKMSVCTDNVTD 720
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     661 SRNTPTRTFNYNFSALANTVTLAGGPSFTSKGLKYFHHFTLSLCGNQGRKMSVCTDNVTD 720

Qy     721 LRIPEGESGFSKSITAYVCQAVIIPPEVTGYKAGVSSQPVSLADRLIGVTTDMTLDGITS 780
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     721 LRIPEGESGFSKSITAYVCQAVIIPPEVTGYKAGVSSQPVSLADRLIGVTTDMTLDGITS 780

Qy     781 PAELFHLESLGIPDVIFFYRSNDVTQSCSSGRSTTIRVRCSPQKTVPGSLLLPGTCSDGT 840
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     781 PAELFHLESLGIPDVIFFYRSNDVTQSCSSGRSTTIRVRCSPQKTVPGSLLLPGTCSDGT 840

Qy     841 CDGCNFHFLWESAAACPLCSVADYHAIVSSCVAGIQKTTYVWREPKLCSGGISLPEQRVT 900
           |||||||||||||||||||||| ||||||||||||||||||||||||||||||||||||||
Db     841 CDGCNFHFLWESAAACPLCSVADYRAIVSSCVAGIQKTTYVWREPKLCSGGISLPEQRVT 900

Qy     901 ICKTIDFWLKVGISAGTCTAILLTVLTCYFWKKNQKLEYKYSKLVMNATLKDCDLPAADS 960
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     901 ICKTIDFWLKVGISAGTCTAILLTVLTCYFWKKNQKLEYKYSKLVMNATLKDCDLPAADS 960

Qy     961 CAIMEGEDVEDDLIFTSKNHSLGR 984
           ||||||||||||||||||    |:
Db     961 CAIMEGEDVEDDLIFTSKKSLFGK 984


RESULT 4
AAU12190
ID   AAU12190 standard; Protein; 1013 AA.
XX
AC   AAU12190;
XX
DT   24-OCT-2001  (first entry)
XX
DE   Human PRO4985 polypeptide sequence.
XX
KW   Human secretory and transmembrane; PRO; mammalian; cancer; lung;
KW   breast; prostate; cervical; tumour necrosis factor-alpha; TNF-alpha;
KW   cartilage; ear; proliferation; glucose; free fatty acid; skeletal muscle;
KW   adipocyte; A-peptide; factor VIIA; gene therapy.
XX
OS   Homo sapiens.
XX
PN   WO200140466-A2.
XX
PD   07-JUN-2001.
XX
PF   01-DEC-2000; 2000WO-US32678.
XX
PR   01-DEC-1999;   99WO-US28301.
PR   01-DEC-1999;   99WO-US28634.
PR   02-DEC-1999;   99WO-US28551.
PR   02-DEC-1999;   99WO-US28564.
PR   02-DEC-1999;   99WO-US28565.
PR   09-DEC-1999;   99US-0170262.
PR   16-DEC-1999;   99WO-US30095.
PR   20-DEC-1999;   99WO-US30911.
PR   20-DEC-1999;   99WO-US30999.
PR   30-DEC-1999;   99WO-US31243.
PR   06-JAN-2000; 2000WO-US00277.
PR   06-JAN-2000; 2000WO-US00376.
PR   11-FEB-2000; 2000WO-US03565.
PR   18-FEB-2000; 2000WO-US04341.
PR   18-FEB-2000; 2000WO-US04342.
PR   22-FEB-2000; 2000WO-US04414.
PR   24-FEB-2000; 2000WO-US04914.
PR   24-FEB-2000; 2000WO-US05004.
PR   01-MAR-2000; 2000WO-US05601.
PR   20-MAR-2000; 2000WO-US07377.
PR   21-MAR-2000; 2000WO-US07532.
PR   30-MAR-2000; 2000WO-US08439.
PR   17-MAY-2000; 2000WO-US13705.
PR   22-MAY-2000; 2000WO-US14042.
PR   30-MAY-2000; 2000WO-US14941.
PR   02-JUN-2000; 2000WO-US15264.
PR   10-NOV-2000; 2000WO-US30873.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2001-408281/43.
DR   N-PSDB; AAS21262.
XX
PT   Isolated, secretory and transmembrane PRO polypeptide used to detect
PT   other PRO polypeptides, link bioactive molecules to cells expressing
PT   PRO polypeptides, and detect the presence of mammalian tumours e.g.
PT   lung, breast, prostate, cervical  -
XX
PS   Claim 12; Fig 38; 813pp; English.
XX
CC   AAU12172-AAU12446 represent novel human secretory and transmembrane
CC   PRO polypeptides. The PRO polypeptides are useful to detect other
CC   PRO polypeptides, to link bioactive molecules to cells expressing
CC   PRO polypeptides, to modulate biological activities of cells expressing
CC   PRO polypeptides, and to detect the presence of mammalian lung, colon,
CC   breast, prostate, rectal, cervical or liver tumours by comparing PRO
CC   polypeptide expression in a cell sample to that in a control sample.
CC   Some of the 275 sequences are also useful to stimulate the release of
CC   tumour necrosis factor-alpha (TNF-alpha) from human blood, the
CC   proliferation or differentiation of chondrocytes, the proliferation or
CC   gene expression in pericyte cells, the release of proteoglycans from
CC   cartilage, the proliferation of inner ear utricular supporting cells or
CC   of T-lymphocytes, the release of a cytokine from peripheral blood
CC   monocytes (PBMCs), or the proliferation of endothelial cells. Some of
CC   the PRO polypeptides may modulate glucose or free fatty acid uptake by
CC   skeletal muscle cells or by adipocytes; or inhibit binding of A-peptide
CC   to factor VIIA. The PRO polypeptides can be used in assays to identify
CC   molecules involved in binding interactions. The polynucleotides encoding
CC   PRO polypeptides can be used to generate probes, antisense RNA/DNA,
CC   transgenic or knock out animals and can be used in gene therapy.
XX
SQ   Sequence   1013 AA;

  Query Match             97.0%;  Score 5341;  DB 22;  Length 1013;
  Best Local Similarity   99.0%;  Pred. No. 0;
  Matches  974;  Conservative    1;  Mismatches    9;  Indels    0;  Gaps    0;
```

```
Qy       1 MAEPGHSHHLSARVRGRTERRIPRLWRLLLWAGTAFQVTQGTGPELHACKESEYHYEYTA 60
           |||||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||
Db       1 MAEPGHSHHLSARVRRRTERRIPRLWRLLLWAGTAFQVTQGTGPELHACKESEYHYEYTA 60

Qy      61 CDSTGSRWRVAVPHTPGLCTSLPDPVKGTECSFSCNAGEFLDMKDQSCKPCAEGRYSLGT 120
           ||||||||||||||||||||| ||||||||||||||||||||||||||||||||||||||||
Db      61 CDSTGSRWRVAVPHTPGLCTSLSDPVKGTECSFSCNAGEFLDMKDQSCKPCAEGRYSLGT 120

Qy     121 GIRFDEWDELPHGFASLSANMELDDSAAESTGNCTSSKWVPRGDYIAFNTDECTATLMYA 180
           |||||||||||||||||||||||||||||||||||||||||||||||| ||||||||||||
Db     121 GIRFDEWDELPHGFASLSANMELDDSAAESTGNCTSSKWVPRGDYIASNTDECTATLMYA 180

Qy     181 VNLKQSGTVNFEYYYPDSSIIFEFFVQNDQCQPNADDSRWMKTTEKGWEFHSVELNRGNN 240
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     181 VNLKQSGTVNFEYYYPDSSIIFEFFVQNDQCQPNADDSRWMKTTEKGWEFHSVELNRGNN 240

Qy     241 VLYWRTTAFSVWTKVPKPVLVRNIAITGVAYTSECFPCKPGTYADKQGSSFCKLCPANSY 300
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     241 VLYWRTTAFSVWTKVPKPVLVRNIAITGVAYTSECFPCKPGTYADKQGSSFCKLCPANSY 300

Qy     301 SNKGETSCHQCDPDKYSEKGSSSCNVRPACTDKDYFYTHTACDANGETQLMYKWAKPKIC 360
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     301 SNKGETSCHQCDPDKYSEKGSSSCNVRPACTDKDYFYTHTACDANGETQLMYKWAKPKIC 360

Qy     361 SEDLEGAVKLPASGVKTHCPPCNPGFFKTNNSTCQPCPYGSYSNGSDCTRCPAGTEPAVG 420
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     361 SEDLEGAVKLPASGVKTHCPPCNPGFFKTNNSTCQPCPYGSYSNGSDCTRCPAGTEPAVG 420

Qy     421 FEYKWWNTLPTNMETTVLSGINFEYKGMTGWEVAGDHIYTAAGASDNDFMILTLVVPGFR 480
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     421 FEYKWWNTLPTNMETTVLSGINFEYKGMTGWEVAGDHIYTAAGASDNDFMILTLVVPGFR 480

Qy     481 PPQSVMADTENKEVARITFVFETLCSVNCELYFMVGVNSRTNTPVETWKGSKGKQSYTYI 540
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     481 PPQSVMADTENKEVARITFVFETLCSVNCELYFMVGVNSRTNTPVETWKGSKGKQSYTYI 540

Qy     541 IEENTTTSFTWAFQRTTFHEASRKYTNDVAKIYSINVTNVMNGVASYCRPCALEASDVGS 600
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     541 IEENTTTSFTWAFQRTTFHEASRKYTNDVAKIYSINVTNVMNGVASYCRPCALEASDVGS 600

Qy     601 SCTSCPAGYYIDRDSGTCHSCPPNTILKAHQPYGVQACVPCGPGTKNNKIHSLCYNDCTF 660
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     601 SCTSCPAGYYIDRDSGTCHSCPPNTILKAHQPYGVQACVPCGPGTKNNKIHSLCYNDCTF 660

Qy     661 SRNTPTRTFNYNFSALANTVTLAGGPSFTSKGLKYFHHFTLSLCGNQGRKMSVCTDNVTD 720
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     661 SRNTPTRTFNYNFSALANTVTLAGGPSFTSKGLKYFHHFTLSLCGNQGRKMSVCTDNVTD 720

Qy     721 LRIPEGESGFSKSITAYVCQAVIIPPEVTGYKAGVSSQPVSLADRLIGVTTDMTLDGITS 780
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     721 LRIPEGESGFSKSITAYVCQAVIIPPEVTGYKAGVSSQPVSLADRLIGVTTDMTLDGITS 780

Qy     781 PAELFHLESLGIPDVIFFYRSNDVTQSCSSGRSTTIRVRCSPQKTVPGSLLLPGTCSDGT 840
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     781 PAELFHLESLGIPDVIFFYRSNDVTQSCSSGRSTTIRVRCSPQKTVPGSLLLPGTCSDGT 840

Qy     841 CDGCNFHFLWESAAACPLCSVADYHAIVSSCVAGIQKTTYVWREPKLCSGGISLPEQRVT 900
           ||||||||||||||||||||||||||||||||| |||| ||||||||||||||||||||||
Db     841 CDGCNFHFLWESAAACPLCSVADYHAIVSSCVAGIQXTTYVXREPKLCSGGISLPEQRVT 900

Qy     901 ICKTIDFWLKVGISAGTCTAILLTVLTCYFWKKNQKLEYKYSKLVMNATLKDCDLPAADS 960
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     901 ICKTIDFWLKVGISAGTCTAILLTVLTCYFWKKNQKLEYKYSKLVMNATLKDCDLPAADS 960

Qy     961 CAIMEGEDVEDDLIFTSKNHSLGR 984
           |||||||||||||||||    |:
Db     961 CAIMEGEDVEDDLIFTSKKSLFGK 984
```

RESULT 5
AAB83850
ID  AAB83850 standard; Protein; 911 AA.

XX
AC  AAB83850;
XX
DT  23-JUL-2001  (first entry)
XX
DE  Amino acid sequence of a human protein expressed in tumour cells.
XX
KW  Tumour cell; immunological disease; autoimmune disease; cancer;
KW  infection.
XX
OS  Homo sapiens.
XX
PN  WO200131003-A1.
XX
PD  03-MAY-2001.
XX
PF  30-OCT-2000; 2000WO-FR03032.
XX
PR  29-OCT-1999;  99FR-0013629.
XX
PA  (FABR ) FABRE MEDICAMENT SA PIERRE.
XX
PI  Delneste Y,  Magistrelli G,  Jeannin P,  Bonnefoy J;
XX
DR  WPI; 2001-328651/34.
DR  N-PSDB; AAF89774.
XX
PT  New nucleic acid, expressed in tumours and lymphoid tissue is useful for
PT  identifying agents for treating tumours and autoimmune disease -
XX
PS  Claim 10; Page 60-63; 85pp; French.
XX
CC  The present sequence represents a human protein expressed in tumour
CC  cells. The polynucleotide is useful for screening cDNA/genomic DNA banks
CC  and for cloning isolated DNA; identifying mutant forms of the gene that
CC  encodes a human protein, where the mutations are associated with
CC  abnormal gene expression, or promoters and regulators of the gene,
CC  particularly for diagnosis; for recombinant expression of the derived
CC  protein; as probes and primers for detection and amplification; and
CC  as antisense therapeutics. The tumour expressed protein is useful for
CC  raising specific antibodies and to screen agents that modulate its
CC  activity, bind to it or interact with it. These agents are potentially
CC  useful for treatment or prevention of diseases associated with abnormal
CC  expression/activity of the protein, particularly immunological diseases
CC  (autoimmune diseases and cancer) or viral, bacterial, fungal or parasitic
CC  infections.
XX
SQ  Sequence  911 AA;

Query Match  90.9%;  Score 5005;  DB 22;  Length 911;
Best Local Similarity  99.7%;  Pred. No. 0;
Matches 908;  Conservative  0;  Mismatches  3;  Indels  0;  Gaps  0;

```
Qy       1 MAEPGHSHHLSARVRGRTERRIPRLWRLLLWAGTAFQVTQGTGPELHACKESEYHYEYTA 60
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1 MAEPGHSHHLSARVRGRTERRIPRLWRLLLWAGTAFQVTQGTGPELHACKESEYHYEYTA 60

Qy      61 CDSTGSRWRVAVPHTPGLCTSLPDPVKGTECSFSCNAGEFLDMKDQSCKPCAEGRYSLGT 120
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      61 CDSTGSRWRVAVPHTPGLCTSLPDPVKGTECSFSCNAGEFLDMKDQSCKPCAEGRYSLGT 120

Qy     121 GIRFDEWDELPHGFASLSANMELDDSAAESTGNCTSSKWVPRGDYIAFNTDECTATLMYA 180
           |||||||||||||||||||||||||||||||||||||||||||||||| ||||||||||||
Db     121 GIRFDEWDELPHGFASLSANMELDDSAAESTGNCTSSKWVPRGDYIASNTDECTATLMYA 180

Qy     181 VNLKQSGTVNFEYYYPDSSIIFEFFVQNDQCQPNADDSRWMKTTEKGWEFHSVELNRGNN 240
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     181 VNLKQSGTVNFEYYYPDSSIIFEFFVQNDQCQPNADDSRWMKTTEKGWEFHSVELNRGNN 240

Qy     241 VLYWRTTAFSVWTKVPKPVLVRNIAITGVAYTSECFPCKPGTYADKQGSSFCKLCPANSY 300
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     241 VLYWRTTAFSVWTKVPKPVLVRNIAITGVAYTSECFPCKPGTYADKQGSSFCKLCPANSY 300
```

```
Qy     301 SNKGETSCHQCDPDKYSEKGSSSCNVRPACTDKDYFYTHTACDANGETQLMYKWAKPKIC 360
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     301 SNKGETSCHQCDPDKYSEKGSSSCNVRPACTDKDYFYTHTACDANGETQLMYKWAKPKIC 360

Qy     361 SEDLEGAVKLPASGVKTHCPPCNPGFFKTNNSTCQPCPYGSYSNGSDCTRCPAGTEPAVG 420
           |||||||||||||||||||||||||||||||||||| ||||||||||||||||||||||||
Db     361 SEDLEGAVKLPASGVKTHCPPCNPGFFKTNNSTCQPCPYGPYSNGSDCTRCPAGTEPAVG 420

Qy     421 FEYKWWNTLPTNMETTVLSGINFEYKGMTGWEVAGDHIYTAAGASDNDFMILTLVVPGFR 480
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     421 FEYKWWNTLPTNMETTVLSGINFEYKGMTGWEVAGDHIYTAAGASDNDFMILTLVVPGFR 480

Qy     481 PPQSVMADTENKEVARITFVFETLCSVNCELYFMVGVNSRTNTPVETWKGSKGKQSYTYI 540
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     481 PPQSVMADTENKEVARITFVFETLCSVNCELYFMVGVNSRTNTPVETWKGSKGKQSYTYI 540

Qy     541 IEENTTTSFTWAFQRTTFHEASRKYTNDVAKIYSINVTNVMNGVASYCRPCALEASDVGS 600
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     541 IEENTTTSFTWAFQRTTFHEASRKYTNDVAKIYSINVTNVMNGVASYCRPCALEASDVGS 600

Qy     601 SCTSCPAGYYIDRDSGTCHSCPPNTILKAHQPYGVQACVPCGPGTKNNKIHSLCYNDCTF 660
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     601 SCTSCPAGYYIDRDSGTCHSCPPNTILKAHQPYGVQACVPCGPGTKNNKIHSLCYNDCTF 660

Qy     661 SRNTPTRTFNYNFSALANTVTLAGGPSFTSKGLKYFHHFTLSLCGNQGRKMSVCTDNVTD 720
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     661 SRNTPTRTFNYNFSALANTVTLAGGPSFTSKGLKYFHHFTLSLCGNQGRKMSVCTDNVTD 720

Qy     721 LRIPEGESGFSKSITAYVCQAVIIPPEVTGYKAGVSSQPVSLADRLIGVTTDMTLDGITS 780
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     721 LRIPEGESGFSKSITAYVCQAVIIPPEVTGYKAGVSSQPVSLADRLIGVTTDMTLDGITS 780

Qy     781 PAELFHLESLGIPDVIFFYRSNDVTQSCSSGRSTTIRVRCSPQKTVPGSLLLPGTCSDGT 840
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     781 PAELFHLESLGIPDVIFFYRSNDVTQSCSSGRSTTIRVRCSPQKTVPGSLLLPGTCSDGT 840

Qy     841 CDGCNFHFLWESAAACPLCSVADYHAIVSSCVAGIQKTTYVWREPKLCSGGISLPEQRVT 900
           |||||||||||||||||||||| ||||||||||||||||||||||||||||||||||||||
Db     841 CDGCNFHFLWESAAACPLCSVADYRAIVSSCVAGIQKTTYVWREPKLCSGGISLPEQRVT 900

Qy     901 ICKTIDFWLKV 911
           |||||||||||
Db     901 ICKTIDFWLKV 911
```

RESULT 6
AAB83851
ID  AAB83851 standard; Protein; 870 AA.
XX
AC  AAB83851;
XX
DT  23-JUL-2001  (first entry)
XX
DE  Amino acid sequence of a human protein expressed in tumour cells.
XX
KW  Tumour cell; immunological disease; autoimmune disease; cancer;
KW  infection.
XX
OS  Homo sapiens.
XX
PN  WO200131003-A1.
XX
PD  03-MAY-2001.
XX
PF  30-OCT-2000; 2000WO-FR03032.
XX
PR  29-OCT-1999;  99FR-0013629.
XX
PA  (FABR ) FABRE MEDICAMENT SA PIERRE.
XX
PI  Delneste Y,  Magistrelli G,  Jeannin P,  Bonnefoy J;
XX
DR  WPI; 2001-328651/34.
DR  N-PSDB; AAF89775.
XX
PT  New nucleic acid, expressed in tumours and lymphoid tissue is useful for
PT  identifying agents for treating tumours and autoimmune disease -
XX
PS  Claim 10; Page 67-70; 85pp; French.
XX
CC  The present sequence represents a human protein expressed in tumour
CC  cells. The polynucleotide is useful for screening cDNA/genomic DNA banks
CC  and for cloning isolated DNA; identifying mutant forms of the gene that
CC  encodes a human protein, where the mutations are associated with
CC  abnormal gene expression, or promoters and regulators of the gene,
CC  particularly for diagnosis; for recombinant expression of the derived
CC  protein; as probes and primers for detection and amplification; and
CC  as antisense therapeutics. The tumour expressed protein is useful for
CC  raising specific antibodies and to screen agents that modulate its
CC  activity, bind to it or interact with it. These agents are potentially
CC  useful for treatment or prevention of diseases associated with abnormal
CC  expression/activity of the protein, particularly immunological diseases
CC  (autoimmune diseases and cancer) or viral, bacterial, fungal or parasitic
CC  infections.
XX
SQ  Sequence  870 AA;

Query Match  86.9%;  Score 4784;  DB 22;  Length 870;
Best Local Similarity  99.7%;  Pred. No. 0;
Matches 867;  Conservative  0;  Mismatches  3;  Indels  0;  Gaps  0;

```
Qy      42 TGPELHACKESEYHYEYTACDSTGSRWRVAVPHTPGLCTSLPDPVKGTECSFSCNAGEFL 101
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1 TGPELHACKESEYHYEYTACDSTGSRWRVAVPHTPGLCTSLPDPVKGTECSFSCNAGEFL 60

Qy     102 DMKDQSCKPCAEGRYSLGTGIRFDEWDELPHGFASLSANMELDDSAAESTGNCTSSKWVP 161
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      61 DMKDQSCKPCAEGRYSLGTGIRFDEWDELPHGFASLSANMELDDSAAESTGNCTSSKWVP 120

Qy     162 RGDYIAFNTDECTATLMYAVNLKQSGTVNFEYYYPDSSIIFEFFVQNDQCQPNADDSRWM 221
           |||||| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     121 RGDYIASNTDECTATLMYAVNLKQSGTVNFEYYYPDSSIIFEFFVQNDQCQPNADDSRWM 180

Qy     222 KTTEKGWEFHSVELNRGNNVLYWRTTAFSVWTKVPKPVLVRNIAITGVAYTSECFPCKPG 281
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     181 KTTEKGWEFHSVELNRGNNVLYWRTTAFSVWTKVPKPVLVRNIAITGVAYTSECFPCKPG 240

Qy     282 TYADKQGSSFCKLCPANSYSNKGETSCHQCDPDKYSEKGSSSCNVRPACTDKDYFYTHTA 341
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     241 TYADKQGSSFCKLCPANSYSNKGETSCHQCDPDKYSEKGSSSCNVRPACTDKDYFYTHTA 300

Qy     342 CDANGETQLMYKWAKPKICSEDLEGAVKLPASGVKTHCPPCNPGFFKTNNSTCQPCPYGS 401
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     301 CDANGETQLMYKWAKPKICSEDLEGAVKLPASGVKTHCPPCNPGFFKTNNSTCQPCPYGP 360

Qy     402 YSNGSDCTRCPAGTEPAVGFEYKWWNTLPTNMETTVLSGINFEYKGMTGWEVAGDHIYTA 461
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     361 YSNGSDCTRCPAGTEPAVGFEYKWWNTLPTNMETTVLSGINFEYKGMTGWEVAGDHIYTA 420

Qy     462 AGASDNDFMILTLVVPGFRPPQSVMADTENKEVARITFVFETLCSVNCELYFMVGVNSRT 521
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     421 AGASDNDFMILTLVVPGFRPPQSVMADTENKEVARITFVFETLCSVNCELYFMVGVNSRT 480

Qy     522 NTPVETWKGSKGKQSYTYIIEENTTTSFTWAFQRTTFHEASRKYTNDVAKIYSINVTNVM 581
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     481 NTPVETWKGSKGKQSYTYIIEENTTTSFTWAFQRTTFHEASRKYTNDVAKIYSINVTNVM 540

Qy     582 NGVASYCRPCALEASDVGSSCTSCPAGYYIDRDSGTCHSCPPNTILKAHQPYGVQACVPC 641
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     541 NGVASYCRPCALEASDVGSSCTSCPAGYYIDRDSGTCHSCPPNTILKAHQPYGVQACVPC 600

Qy     642 GPGTKNNKIHSLCYNDCTFSRNTPTRTFNYNFSALANTVTLAGGPSFTSKGLKYFHHFTL 701
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     601 GPGTKNNKIHSLCYNDCTFSRNTPTRTFNYNFSALANTVTLAGGPSFTSKGLKYFHHFTL 660

Qy     702 SLCGNQGRKMSVCTDNVTDLRIPEGESGFSKSITAYVCQAVIIPPEVTGYKAGVSSQPVS 761
```

```
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    661 SLCGNQGRKMSVCTDNVTDLRIPEGESGFSKSITAYVCQAVIIPPEVTGYKAGVSSQPVS 720

Qy    762 LADRLIGVTTDMTLDGITSPAELFHLESLGIPDVIFFYRSNDVTQSCSSGRSTTIRVRCS 821
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    721 LADRLIGVTTDMTLDGITSPAELFHLESLGIPDVIFFYRSNDVTQSCSSGRSTTIRVRCS 780

Qy    822 PQKTVPGSLLLPGTCSDGTCDGCNFHFLWESAAACPLCSVADYHAIVSSCVAGIQKTTYV 881
          |||||||||||||||||||||||||||||||||||||| ||||||||||||||||||||||
Db    781 PQKTVPGSLLLPGTCSDGTCDGCNFHFLWESAAACPLCSVADYRAIVSSCVAGIQKTTYV 840

Qy    882 WREPKLCSGGISLPEQRVTICKTIDFWLKV 911
          |||||||||||||||||||||||||||||||
Db    841 WREPKLCSGGISLPEQRVTICKTIDFWLKV 870
```

RESULT 7
AAB35328
ID AAB35328 standard; Protein; 750 AA.
XX
AC AAB35328;
XX
DT 08-MAY-2001 (first entry)
XX
DE Human TR13 receptor protein SEQ ID NO: 2.
XX
KW Human; tumour necrosis factor receptor; TR13; TR14; infection;
KW cancer; autoimmune disease; allergy; inflammatory disease;
KW graft rejection; apoptosis; cardiovascular disease; aneurysm.
XX
OS Homo sapiens.
XX
PN WO200105834-A1.
XX
PD 25-JAN-2001.
XX
PF 14-JUL-2000; 2000WO-US19343.
XX
PR 16-JUL-1999; 99US-0144087.
PR 18-AUG-1999; 99US-0149450.
PR 20-AUG-1999; 99US-0149712.
PR 10-SEP-1999; 99US-0153089.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Ruben SM, Ni J, Young PE;
XX
DR WPI; 2001-112682/12.
DR N-PSDB; AAF27997.
XX
PT Nucleic acids encoding 2 human tumor necrosis factor receptor
PT polypeptides ((TR13) and (TR14)), useful for the prevention, diagnosis
PT and treatment of, e.g. cancers, acquired immune deficiency syndrome and
PT hypohidrotic ectodermal dysplasia -
XX
PS Claim 40; Page 369-372; 418pp; English.
XX
CC The present invention provides the protein and coding sequences of the
CC human tumour necrosis factor receptors TR13 and TR14. These sequences are
CC useful in the diagnosis and treatment of many diseases, including cancer,
CC autoimmune diseases, cardiovascular disorders, allergies,
CC neurodegenerative diseases, graft rejection, inflammation, aneurysms and
CC infections.
XX
SQ Sequence 750 AA;

Query Match 70.3%; Score 3870; DB 22; Length 750;
Best Local Similarity 99.0%; Pred. No. 1.6e-295;
Matches 707; Conservative 2; Mismatches 5; Indels 0; Gaps 0;

```
Qy    288 GSSFCKLCPANSYSNKGETSCHQCDPDKYSEKGSSSCNVRPACTDKDYFYTHTACDANGE 347
          |  | :  |:||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     37 GLLFLQTLPSNSYSNKGETSCHQCDPDKYSEKGSSSCNVRPACTDKDYFYTHTACDANGE 96

Qy    348 TQLMYKWAKPKICSEDLEGAVKLPASGVKTHCPPCNPGFFKTNNSTCQPCPYGSYSNGSD 407
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     97 TQLMYKWAKPKICSEDLEGAVKLPASGVKTHCPPCNPGFFKTNNSTCQPCPYGSYSNGSD 156

Qy    408 CTRCPAGTEPAVGFEYKWWNTLPTNMETTVLSGINFEYKGMTGWEVAGDHIYTAAGASDN 467
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    157 CTRCPAGTEPAVGFEYKWWNTLPTNMETTVLSGINFEYKGMTGWEVAGDHIYTAAGASDN 216

Qy    468 DFMILTLVVPGFRPPQSVMADTENKEVARITFVFETLCSVNCELYFMVGVNSRTNTPVET 527
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    217 DFMILTLVVPGFRPPQSVMADTENKEVARITFVFETLCSVNCELYFMVGVNSRTNTPVET 276

Qy    528 WKGSKGKQSYTYIIEENTTTSFTWAFQRTTFHEASRKYTNDVAKIYSINVTNVMNGVASY 587
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    277 WKGSKGKQSYTYIIEENTTTSFTWAFQRTTFHEASRKYTNDVAKIYSINVTNVMNGVASY 336

Qy    588 CRPCALEASDVGSSCTSCPAGYYIDRDSGTCHSCPPNTILKAHQPYGVQACVPCGPGTKN 647
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    337 CRPCALEASDVGSSCTSCPAGYYIDRDSGTCHSCPPNTILKAHQPYGVQACVPCGPGTKN 396

Qy    648 NKIHSLCYNDCTFSRNTPTRTFNYNFSALANTVTLAGGPSFTSKGLKYFHHFTLSLCGNQ 707
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    397 NKIHSLCYNDCTFSRNTPTRTFNYNFSALANTVTLAGGPSFTSKGLKYFHHFTLSLCGNQ 456

Qy    708 GRKMSVCTDNVTDLRIPEGESGFSKSITAYVCQAVIIPPEVTGYKAGVSSQPVSLADRLI 767
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    457 GRKMSVCTDNVTDLRIPEGESGFSKSITAYVCQAVIIPPEVTGYKAGVSSQPVSLADRLI 516

Qy    768 GVTTDMTLDGITSPAELFHLESLGIPDVIFFYRSNDVTQSCSSGRSTTIRVRCSPQKTVP 827
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    517 GVTTDMTLDGITSPAELFHLESLGIPDVIFFYRSNDVTQSCSSGRSTTIRVRCSPQKTVP 576

Qy    828 GSLLLPGTCSDGTCDGCNFHFLWESAAACPLCSVADYHAIVSSCVAGIQKTTYVWREPKL 887
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    577 GSLLLPGTCSDGTCDGCNFHFLWESAAACPLCSVADYHAIVSSCVAGIQKTTYVWREPKL 636

Qy    888 CSGGISLPEQRVTICKTIDFWLKVGISAGTCTAILLTVLTCYFWKKNQKLEYKYSKLVMN 947
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    637 CSGGISLPEQRVTICKTIDFWLKVGISAGTCTAILLTVLTCYFWKKNQKLEYKYSKLVMN 696

Qy    948 ATLKDCDLPAADSCAIMEGEDVEDDLIFTSKNHSLGRSNHLPPRGLLMDLTQCR 1001
          |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    697 ATLKDCDLPAADSCAIMEGEDVEDDLIFTSKNHSLGRSNHLPPRGLLMDLTQCR 750
```

RESULT 8
AAB70256
ID AAB70256 standard; protein; 1027 AA.
XX
AC AAB70256;
XX
DT 10-MAY-2001 (first entry)
XX
DE TR16-long receptor protein.
XX
KW TR16 recptor; tumour necrosis factor receptor superfamily;
KW apoptosis; inflammatory; cancer; immune; neurodegenerative.
XX
OS Unidentified.
XX
PN WO200112671-A1.
XX
PD 22-FEB-2001.
XX
PF 10-AUG-2000; 2000WO-US21885.
XX
PR 12-AUG-1999; 99US-0148348.
PR 13-AUG-1999; 99US-0148683.
PR 13-AUG-1999; 99US-0148870.
PR 16-AUG-1999; 99US-0148758.
PR 17-AUG-1999; 99US-0149181.
PR 18-AUG-1999; 99US-0149453.

PR 19-AUG-1999; 99US-0149498.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Ruben SM, Young PE, Baker KP;
XX
DR WPI; 2001-138754/14.
XX
PT New nucleic acid molecule encoding a TR16 tumor necrosis factor
PT receptor polypeptide, useful for the diagnosis and treatment of cancer,
PT autoimmune disorders and cardiovascular diseases -
XX
PS Disclosure; Fig 4; 286pp; English.
XX
CC The present invention relates to a TR16 receptor (tumour necrosis
CC factor receptor superfamily). The invention is useful treating
CC diseases and disorders associated with the inhibited or increased
CC apoptosis. In particular inflammatory diseases, cancers, immune and
CC neurodegenerative disorders may be treated.
XX
SQ Sequence 1027 AA;

Query Match 54.2%; Score 2982.5; DB 22; Length 1027;
Best Local Similarity 53.6%; Pred. No. 1.7e-225;
Matches 530; Conservative 168; Mismatches 270; Indels 21; Gaps 11;

```
Qy      15 RGRTERRIPR---LWRL----LLWAGTAFQVTQGTGPELHACKESEYHYEYTACDSTGSR 67
           |||:    |     | |       |||    :   :   |  |:| :||:||| |||:|||
Db      23 RGRSPPWSPAWICCWALAGCQAAWAG---DLPSSSSRPLPPCQEKDYHFEYTECDSSGSR 79

Qy      68 WRVAVPHTPGLCTSLPDPVKGTECSFSCNAGEFLDMKDQSCKPCAEGRYSLGTGIRFDEW 127
           ||||:|::   |: |||||:| ||:||| :||:|:||:| |   | || ||||:||:||||
Db      80 WRVAIPNSAVDCSGLPDPVRGKECTFSCASGEYLEMKNQVCSKCGEGTYSLGSGIKFDEW 139

Qy     128 DELPHGFASLSANMELDDSAAES-TGNCTSSKWVPRGDYIAFNTDECTATLMYAVNLKQS 186
           |||| ||:::  |:     ::|    | :| |:|||:||  | |:|| :|:|||:||:|
Db     140 DELPAGFSNIATFMDTVVGPSDSRPDGCNNSSWIPRGNYIESNRDDCTVSLIYAVHLKKS 199

Qy     187 GTVNFEYYYPDSSIIFEFFVQNDQCQP-NADDSRWMKTTEKG-WEFHSVELNRGNNVLYW 244
           | | ||| | |::| ||||:|||||  :    :|:| |: | |  ||| |  | |:|||
Db     200 GYVFFEYQYVDNNIFFEFFIQNDQCQEMDTTTDKWVKLTDNGEWGSHSVMLKSGTNILYW 259

Qy     245 RTTAFSVWTKVPKPVLVRNIAITGVAYTSECFPCKPGTYADKQGSSFCKLCPANSYSNKG 304
           |||   : :|  |||||:|| | |||||||||||||||:::| ||  |::|| |:|| ||
Db     260 RTTGILMGSKAVKPVLVKNITIEGVAYTSECFPCKPGTFSNKPGSFNCQVCPRNTYSEKG 319

Qy     305 ETSCHQC-DPDKYSEKGSSSCNVRPACTDKDYFYTHTACDANGETQLMYKWAKPKICSED 363
           | :| |  ::|  ||| |  || || ||||  || ||  |:||:|||| :|||| ||
Db     320 AKECIRCKDDSQFS--GSSECTERPPCTTKDYFQIHTPCDEEGKTQIMYKWIEPKICRED 377

Qy     364 LEGAVKLPASGVKTHCPPCNPGFFKTNNSTCQPCPYGSYSNGS-DCTRCPAGTEPAVGFE 422
           |  |::|| || |  |||||||:   :|:| ||| |::|:|: :|  ||||||||:|||
Db     378 LTDAIRLPPSGEKKDCPPCNPGFYNNGSSSCHPCPPGTFSDGTKECRPCPAGTEPALGFE 437

Qy     423 YKWWNTLPTNMETTVLSGINFEYKGMTGWEVAGDHIYTAAGASDNDFMILTLVVPGFRPP 482
           ||||| || ||:|:  :  | :  || |||||||||| : || ||||::|| | :|||:||
Db     438 YKWWNVLPGNMKTSCFNVGNSKCDGMNGWEVAGDHIQSGAGGSDNDYLILNLHIPGFKPP 497

Qy     483 QSVMADTENKEVARITFVFETLCSVNCELYFMVGVNSRTNTPVETWKGSKGKQSYTYIIE 542
           | |      |: |||||||||| :| ||||| :| ::   ||:| |:| ||:||:||
Db     498 TS-MTGATGSELGRITFVFETLCSADCVLYFMVDINRKSTNVVESWGGTKEKQAYTHIIF 556

Qy     543 ENTTTSFTWAFQRTTFHEASRKYTNDVAKIYSINVTNVMNGVASYCRPCALEASDVGSSC 602
           :| | :|||||||   : :|:: ||: ||||| || ::|||| || ||| :   ||||
Db     557 KNATFTFTWAFQRTNQGQDNRRFINDMVKIYSITATNAVDGVASSCRACALGSEQSGSSC 616

Qy     603 TSCPAGYYIDRDSGTCHSCPPNTILKAHQPYGVQACVPCGPGTKNNKIHSLCYNDCTFSR 662
           || |:||:::  |  |||:| |  || || :||:|||||:||| ||:||:|| |
Db     617 VPCPPGHYIEKETNQCKECPPDTYLSIHQVYGKEACIPCGPGSKNNQDHSVCYSDCFFYH 676

Qy     663 NTPTRTFNYNFSALANTVTLAGGPSFTSKGLKYFHHFTLSLCGNQGRKMSVCTDNVTDLR 722
           :  :|:|| |::  :|  |||||||| |||| | :||||::|:||::||:|:||
Db     677 EKENQILHYDFSNLSSVGSLMNGPSFTSKGTKYFHFFNISLCGHEGKKMALCTNNITDFT 736
```

Qy     723 IPE---GESGFSKSITAYVCQAVIIPPEVTGYKAGVSSQPVSLADRLIGVTTDMTLDGIT 779
           : |   |   ::  : |:|||: ||| |  |::| :||| : |||  |||| : ||  |
Db     737 VKEIVAGSDDYTNLVGAFVCQSTIIPSESKGFRAALSSQSIILADTFIGVTVETTLKNIN 796

Qy     780 SPAELFHLESLGIPDVIFFYRSNDVTQSCSSGRSTTIRVRCSPQKTVPGSLLLPGTCSDG 839
           ::| : :  |||| |||:|:  | || :|||| :::||:| |:  | : :|  |  |
Db     797 IKEDMFPVPTSQIPDVHFFYKSSTATTSCINGRSTAVKMRCNPTKSGAGVISVPSKCPAG 856

Qy     840 TCDGCNFHFLWESAAACPLCSVADYHAIVSSCVAGIQKTTYVWREPKLCSGGISLPEQRV 899
           ||||| |:|||||| |||||:  |:| |  :|  | |:| ||| ||| |  |||||||:::
Db     857 TCDGCTFYFLWESAEACPLCTEHDFHEIEGACKRGFQETLYVWNEPKWCIKGISLPEKKL 916

Qy     900 TICKTIDFWLKVGISAGTCTAILLTVLTCYFWKKNQKLEYKYSKLVMNATLKDCDLPAAD 959
           |:|:|||||||  |  ||:||  |||||||||||||||||||||    |:|:|||||
Db     917 ATCETVDFWLKVGAGVGAFTAVLLVALTCYFWKKNQKLEYKYSKLVMTTNSKECELPAAD 976

Qy     960 SCAIMEGEDVEDDLIFTSKNHSLGRSNHL 988
           ||||||||| |:::::::|   ||:   |
Db     977 SCAIMEGEDNEEEVVYSNKQSLLGKLKSL 1005

RESULT 9
AAB70255
ID AAB70255 standard; protein; 963 AA.
XX
AC AAB70255;
XX
DT 10-MAY-2001 (first entry)
XX
DE TR16-short receptor protein.
XX
KW TR16 recptor; tumour necrosis factor receptor superfamily;
KW apoptosis; inflammatory; cancer; immune; neurodegenerative.
XX
OS Unidentified.
XX
PN WO200112671-A1.
XX
PD 22-FEB-2001.
XX
PF 10-AUG-2000; 2000WO-US21885.
XX
PR 12-AUG-1999; 99US-0148348.
PR 13-AUG-1999; 99US-0148683.
PR 13-AUG-1999; 99US-0148870.
PR 16-AUG-1999; 99US-0148758.
PR 17-AUG-1999; 99US-0149181.
PR 18-AUG-1999; 99US-0149453.
PR 19-AUG-1999; 99US-0149498.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Ruben SM, Young PE, Baker KP;
XX
DR WPI; 2001-138754/14.
XX
PT New nucleic acid molecule encoding a TR16 tumor necrosis factor
PT receptor polypeptide, useful for the diagnosis and treatment of cancer,
PT autoimmune disorders and cardiovascular diseases -
XX
PS Claim 1; Fig 1; 286pp; English.
XX
CC The present invention relates to a TR16 receptor (tumour necrosis
CC factor receptor superfamily). The invention is useful treating
CC diseases and disorders associated with the inhibited or increased
CC apoptosis. In particular inflammatory diseases, cancers, immune and
CC neurodegenerative disorders may be treated.
XX
SQ Sequence 963 AA;

Query Match 51.1%; Score 2815.5; DB 22; Length 963;
Best Local Similarity 52.8%; Pred. No. 2.2e-212;

Matches 501; Conservative 161; Mismatches 261; Indels 25; Gaps 12;

```
Qy      15 RGRTERRIPR---LWRL----LLWAGTAFQVTQGTGPELHACKESEYHYEYTACDSTGSR 67
           |||:    |     | |      |||    :   :   |  |:| :||:||| |||:|||
Db      23 RGRSPPWSPAWICCWALAGCQAAWAG---DLPSSSSRPLPPCQEKDYHFEYTECDSSGSR 79

Qy      68 WRVAVPHTPGLCTSLPDPVKGTECSFSCNAGEFLDMKDQSCKPCAEGRYSLGTGIRFDEW 127
           ||||:|::   |: |||||:| ||:||| :||:|:||:| |  | || ||||:||:|||||
Db      80 WRVAIPNSAVDCSGLPDPVRGKECTFSCASGEYLEMKNQVCSKCGEGTYSLGSGIKFDEW 139

Qy     128 DELPHGFASLSANMELDDSAAES-TGNCTSSKWVPRGDYIAFNTDECTATLMYAVNLKQS 186
           |||| ||:::  |:     ::|    | :| |:|||:||  | |:|| :|:|||:||:|
Db     140 DELPAGFSNIATFMDTVVGPSDSRPDGCNNSSWIPRGNYIESNRDDCTVSLIYAVHLKKS 199

Qy     187 GTVNFEYYYPDSSIIFEFFVQNDQCQP-NADDSRWMKTTEKG-WEFHSVELNRGNNVLYW 244
           | | ||| | |::| ||||:||||||  :    :|:| |: | |  ||| |  | |:|||
Db     200 GYVFFEYQYVDNNIFFEFFIQNDQCQEMDTTTDKWVKLTDNGEWGSHSVMLKSGTNILYW 259

Qy     245 RTTAFSVWTKVPKPVLVRNIAITGVAYTSECFPCKPGTYADKQGSSFCKLCPANSYSNKG 304
           |||   : :|  |||||:|| | |||||||||||||||:::| ||  |:::|| |:|| ||
Db     260 RTTGILMGSKAVKPVLVKNITIEGVAYTSECFPCKPGTFSNKPGSFNCQVCPRNTYSEKG 319

Qy     305 ETSCHQC-DPDKYSEKGSSSCNVRPACTDKDYFYTHTACDANGETQLMYKWAKPKICSED 363
             | :| |  ::|  ||| |  || || ||||  || ||  |:||:|||| :|||| ||
Db     320 AKECIRCKDDSQFS--GSSECTERPPCTTKDYFQIHTPCDEEGKTQIMYKWIEPKICRED 377

Qy     364 LEGAVKLPASGVKTHCPPCNPGFFKTNNSTCQPCPYGSYSNGS-DCTRCPAGTEPAVGFE 422
           |  |::|| || |  |||||||:   :|:| ||| |::|:|: :|  |||||||:|||
Db     378 LTDAIRLPPSGEKKDCPPCNPGFYNNGSSSCHPCPPGTFSDGTKECRPCPAGTEPALGFE 437

Qy     423 YKWWNTLPTNMETTVLSGINFEYKGMTGWEVAGDHIYTAAGASDNDFMILTLVVPGFRPP 482
           ||||| || ||:|:  :  | :  || |||||||||| : || ||||::|| | :|||:||
Db     438 YKWWNVLPGNMKTSCFNVGNSKCDGMNGWEVAGDHIQSGAGGSDNDYLILNLHIPGFKPP 497

Qy     483 QSVMADTENKEVARITFVFETLCSVNCELYFMVGVNSRTNTPVETWKGSKGKQSYTYIIE 542
             | |     |: |||||||||| :| ||||| :| ::   ||:| |:| ||:||:||
Db     498 TS-MTGATGSELGRITFVFETLCSADCVLYFMVDINRKSTNVVESWGGTKEKQAYTHIIF 556

Qy     543 ENTTTSFTWAFQRTTFHEASRKYTNDVAKIYSINVTNVMNGVASYCRPCALEASDVGSSC 602
           :| | :|||||||||   : :|:: ||: |||||  || ::|||| || ||| :   ||||
Db     557 KNATFTFTWAFQRTNQGQDNRRFINDMVKIYSITATNAVDGVASSCRACALGSEQSGSSC 616

Qy     603 TSCPAGYYIDRDSGTCHSCPPNTILKAHQPYGVQACVPCGPGTKNNKIHSLCYNDCTFSR 662
             || |:||:::  |  |||:| |  || || :||:|||||:||: ||:||:|| |
Db     617 VPCPPGHYIEKETNQCKECPPDTYLSIHQVYGKEACIPCGPGSKNNQDHSVCYSDCFFYH 676

Qy     663 NTPTRTFNYNFSALANTVTLAGGPSFTSKGLKYFHHFTLSLCGNQGRKMSVCTDNVTDLR 722
           :  :|:|| |::  :|  |||||||| |||| | :||||::|:||::||:|:||
Db     677 EKENQILHYDFSNLSSVGSLMNGPSFTSKGTKYFHFFNISLCGHEGKKMALCTNNITDFT 736

Qy     723 IPE---GESGFSKSITAYVCQAVIIPPEVTGYKAGVSSQPVSLADRLIGVTTDMTLDGIT 779
           : |   |   ::  : |:|||: ||| |  |::| :||| : |||  |||| : ||  |
Db     737 VKEIVAGSDDYTNLVGAFVCQSTIIPSESKGFRAALSSQSIILADTFIGVTVETTLKNIN 796

Qy     780 SPAELFHLESLGIPDVIFFYRSNDVTQSCSSGRSTTIRVRCSPQKTVPGSLLLPGTCSDG 839
             ::| : :  |||| |||:|:  | || :|||| :::||:| |:  | : :|  |  |
Db     797 IKEDMFPVPTSQIPDVHFFYKSSTATTSCINGRSTAVKMRCNPTKSGAGVISVPSKCPAG 856

Qy     840 TCDGCNFHFLWESAAACPLCSVADYHAIVSSCVAGIQKTTYVWREPKLCSGGISLPEQRV 899
           ||||| |:|||||| |||||:  |:| |  :|  | |:| ||| ||| |  ||||||:::
Db     857 TCDGCTFYFLWESAEACPLCTEHDFHEIEGACKRGFQETLYVWNEPKWCIKGISLPEKKL 916

Qy     900 TICKTIDFWLKVGISAGTCTAILLTVLTCYFWKKNQKLEYKYSKLVMN 947
             |:|:|||||||   |  ||:||  |||||||||| :    | ::|
Db     917 ATCETVDFWLKVGAGVGAFTAVLLVALTCYFWKKNQKKK----KTILN 960
```

RESULT 10
AAY59972
ID AAY59972 standard; Protein; 495 AA.
XX
AC AAY59972;
XX
DT 31-JAN-2000 (first entry)
XX
DE Human endometrium tumour EST encoded protein 32.
XX
KW Endometrium; human; tumour; cancer; anticancer; cytostatic; EST:
KW treatment; uterine; gene therapy; expressed sequence tag.
XX
OS Homo sapiens.
XX
PN DE19817948-A1.
XX
PD 21-OCT-1999.
XX
PF 17-APR-1998; 98DE-1017948.
XX
PR 17-APR-1998; 98DE-1017948.
XX
PA (META-) METAGEN GES GENOMFORSCHUNG MBH.
XX
PI Rosenthal A, Specht T, Hinzmann B, Schmitt A, Pilarsky C, Dahl E;
XX
DR WPI; 1999-591957/51.
DR N-PSDB; AAZ41991.
XX
PT New nucleic acid sequences expressed in uterine cancer tissues, and
PT derived polypeptides, for treatment of uterine and endometrial cancer
PT and identification of therapeutic agents -
XX
PS Claim 23; Page 287; 444pp; German.
XX
CC This invention describes novel human nucleic acid (cDNA) sequences (A),
CC that are highly expressed in uterine tumour tissue and which have
CC anticancer and cytostatic activity. (A) are used (i) for recombinant
CC expression of polypeptides (B) and (ii) to isolate complete genes. (B)
CC are used (i) to identify agents suitable for treatment of uterine or
CC endometrial cancer; (ii) directly for treating these forms of cancer
CC (including expression from gene therapy vectors) and (iii) for
CC generation of specific antibodies. (A) are identified by assembling ESTs
CC (expressed sequence tags) from a particular tissue type before comparison
CC of expression patterns. This allows a significantly longer fragment of
CC the gene to be revealed, so should reduce the number of failures
CC associated with the fact that ESTs from different libraries may represent
CC different parts of the same unknown gene, distorting the estimated
CC frequency of occurrence in a particular tissue. AAY59941-Y60328 represent
CC protein fragments encoded by the human endometrium tumour cDNA library
CC derived EST fragments represented in AAZ41981-Z42121.
XX
SQ Sequence 495 AA;

Query Match 45.2%; Score 2491; DB 20; Length 495;
Best Local Similarity 98.9%; Pred. No. 2.9e-187;
Matches 461; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

```
Qy     519 SRTNTPVETWKGSKGKQSYTYIIEENTTTSFTWAFQRTTFHEASRKYTNDVAKIYSINVT 578
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1 SRTNTPVETWKGSKGKQSYTYIIEENTTTSFTWAFQRTTFHEASRKYTNDVAKIYSINVT 60

Qy     579 NVMNGVASYCRPCALEASDVGSSCTSCPAGYYIDRDSGTCHSCPPNTILKAHQPYGVQAC 638
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      61 NVMNGVASYCRPCALEASDVGSSCTSCPAGYYIDRDSGTCHSCPPNTILKAHQPYGVQAC 120

Qy     639 VPCGPGTKNNKIHSLCYNDCTFSRNTPTRTFNYNFSALANTVTLAGGPSFTSKGLKYFHH 698
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     121 VPCGPGTKNNKIHSLCYNDCTFSRNTPTRTFNYNFSALANTVTLAGGPSFTSKGLKYFHH 180

Qy     699 FTLSLCGNQGRKMSVCTDNVTDLRIPEGESGFSKSITAYVCQAVIIPPEVTGYKAGVSSQ 758
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     181 FTLSLCGNQGRKMSVCTDNVTDLRIPEGESGFSKSITAYVCQAVIIPPEVTGYKAGVSSQ 240

Qy     759 PVSLADRLIGVTTDMTLDGITSPAELFHLESLGIPDVIFFYRSNDVTQSCSSGRSTTIRV 818
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     241 PVSLADRLIGVTTDMTLDGITSPAELFHLESLGIPDVIFFYRSNDVTQSCSSGRSTTIRV 300
```

```
Qy    819 RCSPQKTVPGSLLLPGTCSDGTCDGCNFHFLWESAAACPLCSVADYHAIVSSCVAGIQKT 878
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    301 RCSPQKTVPGSLLLPGTCSDGTCDGCNFHFLWESAAACPLCSVADYHAIVSSCVAGIQKT 360

Qy    879 TYVWREPKLCSGGISLPEQRVTICKTIDFWLKVGISAGTCTAILLTVLTCYFWKKNQKLE 938
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    361 TYVWREPKLCSGGISLPEQRVTICKTIDFWLKVGISAGTCTAILLTVLTCYFWKKNQKLE 420

Qy    939 YKYSKLVMNATLKDCDLPAADSCAIMEGEDVEDDLIFTSKNHSLGR 984
          |||||||||||||||||||||||||||||||||||||||||||||||
Db    421 YKYSKLVMNATLKDCDLPAADSCAIMEGEDVEDDLIFTSKKSLFGK 466
```

RESULT 11
AAB83853
ID AAB83853 standard; Protein; 383 AA.
XX
AC AAB83853;
XX
DT 23-JUL-2001 (first entry)
XX
DE Amino acid sequence of a human protein expressed in tumour cells.
XX
KW Tumour cell; immunological disease; autoimmune disease; cancer;
KW infection.
XX
OS Homo sapiens.
XX
PN WO200131003-A1.
XX
PD 03-MAY-2001.
XX
PF 30-OCT-2000; 2000WO-FR03032.
XX
PR 29-OCT-1999; 99FR-0013629.
XX
PA (FABR ) FABRE MEDICAMENT SA PIERRE.
XX
PI Delneste Y, Magistrelli G, Jeannin P, Bonnefoy J;
XX
DR WPI; 2001-328651/34.
DR N-PSDB; AAF89777.
XX
PT New nucleic acid, expressed in tumours and lymphoid tissue is useful for
PT identifying agents for treating tumours and autoimmune disease -
XX
PS Claim 10; Page 74-75; 85pp; French.
XX
CC The present sequence represents a human protein expressed in tumour
CC cells. The polynucleotide is useful for screening cDNA/genomic DNA banks
CC and for cloning isolated DNA; identifying mutant forms of the gene that
CC encodes a human protein, where the mutations are associated with
CC abnormal gene expression, or promoters and regulators of the gene,
CC particularly for diagnosis; for recombinant expression of the derived
CC protein; as probes and primers for detection and amplification; and
CC as antisense therapeutics. The tumour expressed protein is useful for
CC raising specific antibodies and to screen agents that modulate its
CC activity, bind to it or interact with it. These agents are potentially
CC useful for treatment or prevention of diseases associated with abnormal
CC expression/activity of the protein, particularly immunological diseases
CC (autoimmune diseases and cancer) or viral, bacterial, fungal or parasitic
CC infections.
XX
SQ Sequence 383 AA;

```
  Query Match           38.5%;  Score 2119;  DB 22;  Length 383;
  Best Local Similarity 99.5%;  Pred. No. 3.7e-158;
  Matches  381;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy    136 SLSANMELDDSAAESTGNCTSSKWVPRGDYIAFNTDECTATLMYAVNLKQSGTVNFEYYY 195
          |||||||||||||||||||||||||||||||| ||||||||||||||||||||||||||||
Db      1 SLSANMELDDSAAESTGNCTSSKWVPRGDYIASNTDECTATLMYAVNLKQSGTVNFEYYY 60

Qy    196 PDSSIIFEFFVQNDQCQPNADDSRWMKTTEKGWEFHSVELNRGNNVLYWRTTAFSVWTKV 255
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     61 PDSSIIFEFFVQNDQCQPNADDSRWMKTTEKGWEFHSVELNRGNNVLYWRTTAFSVWTKV 120

Qy    256 PKPVLVRNIAITGVAYTSECFPCKPGTYADKQGSSFCKLCPANSYSNKGETSCHQCDPDK 315
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    121 PKPVLVRNIAITGVAYTSECFPCKPGTYADKQGSSFCKLCPANSYSNKGETSCHQCDPDK 180

Qy    316 YSEKGSSSCNVRPACTDKDYFYTHTACDANGETQLMYKWAKPKICSEDLEGAVKLPASGV 375
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    181 YSEKGSSSCNVRPACTDKDYFYTHTACDANGETQLMYKWAKPKICSEDLEGAVKLPASGV 240

Qy    376 KTHCPPCNPGFFKTNNSTCQPCPYGSYSNGSDCTRCPAGTEPAVGFEYKWWNTLPTNMET 435
          |||||||||||||||||||||| |||||||||||||||||||||||||||||||||||||||
Db    241 KTHCPPCNPGFFKTNNSTCQPCPYGPYSNGSDCTRCPAGTEPAVGFEYKWWNTLPTNMET 300

Qy    436 TVLSGINFEYKGMTGWEVAGDHIYTAAGASDNDFMILTLVVPGFRPPQSVMADTENKEVA 495
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    301 TVLSGINFEYKGMTGWEVAGDHIYTAAGASDNDFMILTLVVPGFRPPQSVMADTENKEVA 360

Qy    496 RITFVFETLCSVNCELYFMVGVN 518
          |||||||||||||||||||||||
Db    361 RITFVFETLCSVNCELYFMVGVN 383
```

RESULT 12
AAB85768
ID AAB85768 standard; Protein; 372 AA.
XX
AC AAB85768;
XX
DT 29-OCT-2001 (first entry)
XX
DE Human seven-transmembrane protein 50288 sequence.
XX
KW seven-transmembrane protein; G-protein coupled receptor; GPCR; human;
KW 17724; 50288; 31945; antiinflammatory; antiulcer; cytostatic; virucide;
KW hepatotropic; immunosuppressive; gynecological; neuroprotective;
KW anti-HIV; immunostimulant; dermatological; antiatherosclerotic; cardiant;
KW antianemic; antiParkinsonian; nephrotropic; antithyroid; hemostatic;
KW cerebroprotective; osteopathic; analgesic; gene therapy; nootropic.
XX
OS Homo sapiens.
XX
PN WO200159117-A2.
XX
PD 16-AUG-2001.
XX
PF 12-FEB-2001; 2001WO-US04536.
XX
PR 11-FEB-2000; 2000US-0182061.
XX
PA (MILL-) MILLENNIUM PHARM INC.
XX
PI Glucksmann MA, Silos-Santiago I;
XX
DR WPI; 2001-514670/56.
DR N-PSDB; AAH76195, AAH76196.
XX
PT New seven-transmembrane protein/G-protein coupled receptor polypeptides
PT and polynucleotides for diagnosing, treating seven-transmembrane
PT protein/receptor-related disorders and to identify modulators of
PT therapeutic use -
XX
PS Claim 8; Page 139-141; 144pp; English.
XX
CC The invention provides isolated seven-transmembrane protein/G-protein
CC coupled receptor polypeptides selected from 17724, 50288, 31945 proteins.
CC The polypeptides can be expressed by standard recombinant methodology.
CC Modulators of the polypeptides can be identified using a competition
CC binding assay or an assay for receptor-mediated signal transduction. The
CC polypeptides and polynucleotides are useful as reagents or targets in
CC seven-transmembrane protein/receptor assays applicable to treatment and

```
CC   diagnosis of seven-transmembrane protein/receptor-mediated disorders
CC   (see AAH76191 for a detailed description of the various disorders that
CC   can be treated or diagnosed using the polypeptides). The polynucleotides
CC   are useful to detect mutations in genes and gene expression products such
CC   as mRNA, as antisense constructs to control gene expression and for
CC   chromosome identification. The present sequence represents the human
CC   seven transmembrane protein 50288 sequence.
XX
SQ   Sequence   372 AA;

  Query Match             32.0%;  Score 1761.5;  DB 22;  Length 372;
  Best Local Similarity   96.7%;  Pred. No. 4.8e-130;
  Matches  318;  Conservative    2;  Mismatches    6;  Indels    3;  Gaps    1;

Qy       1 MAEPGHSHHLSARVRGRTERRIPRLWRLLLWAGTAFQVTQGTGPELHACKESEYHYEYTA 60
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1 MAEPGHSHHLSARVRGRTERRIPRLWRLLLWAGTAFQVTQGTGPELHACKESEYHYEYTA 60

Qy      61 CDSTGSRWRVAVPHTPGLCTSLPDPVKGTECSFSCNAGEFLDMKDQSCKPCAEGRYSLGT 120
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      61 CDSTGSRWRVAVPHTPGLCTSLPDPVKGTECSFSCNAGEFLDMKDQSCKPCAEGRYSLGT 120

Qy     121 GIRFDEWDELPHGFASLSANMELDDSAAESTGNCTSSKWVPRGDYIAFNTDECTATLMYA 180
           ||||||||||||||||||||||||||||||||||||||||||| ||||||||||||
Db     121 GIRFDEWDELPHGFASLSANMELDDSAAESTGNCTSSKWVPRGDYIASNTDECTATLMYA 180

Qy     181 VNLKQSGTVNFEYYYPDSSIIFEFFVQNDQCQPNADDSRWMKTTEKGWEFHSVELNRGNN 240
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     181 VNLKQSGTVNFEYYYPDSSIIFEFFVQNDQCQPNADDSRWMKTTEKGWEFHSVELNRGNN 240

Qy     241 VLYWRTTAFSVWTKVPKPVLVRNIAITGVAYTSECFPCKPGTYADKQGSSFCKLCPANSY 300
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     241 VLYWRTTAFSVWTKVPKPVLVRNIAITGVAYTSECFPCKPGTYADKQGSSFCKLCPANSY 300

Qy     301 SNKGETSCHQCDPDKYS---EKGSSSCNV 326
           |||||||||||||||||    :|  |  :
Db     301 SNKGETSCHQCDPDKYSGDVSEGGKSLGI 329


RESULT 13
AAB48377
ID   AAB48377 standard; Protein; 464 AA.
XX
AC   AAB48377;
XX
DT   20-APR-2001  (first entry)
XX
DE   Human SEC10 protein sequence (clone ID 1795045.0.77).
XX
KW   SECX; cytostatic; gynecological; gene therapy; screening assay; human;
KW   SEC10; chromosomal mapping; forensic biology; cell proliferation; cancer;
KW   cell differentiation; immune associated disorder; gestational disease.
XX
OS   Homo sapiens.
XX
PN   WO200078802-A2.
XX
PD   28-DEC-2000.
XX
PF   23-JUN-2000; 2000WO-US17328.
XX
PR   23-JUN-1999;   99US-0140584.
PR   20-JUL-1999;   99US-0144722.
PR   16-SEP-1999;   99US-0154520.
PR   22-JUN-2000; 2000US-0604286.
XX
PA   (CURA-) CURAGEN CORP.
XX
PI   Shimkets RA,  Fernandes E,  Vernet C,  Yang M,  Boldog FL;
PI   Herrmann JL;
XX
DR   WPI; 2001-071385/08.
DR   N-PSDB; AAC84891.
XX
PT   Polynucleotides encoding SECX proteins useful for treating disease
PT   characterized by an aberrant level of cell proliferation and/or
PT   differentiation like cancer or immune associated disorders -
XX
PS   Claim 1; Fig 10; 132pp; English.
XX
CC   The invention relates to human SECX polypeptides and polynucleotides
CC   encoding them. The SECX polypeptides can be expressed by standard
CC   recombinant methodology.  The SECX polypeptides are useful for treating
CC   or preventing a SECX-associated disorder. The invention is useful in
CC   screening assays; detection assays (e.g. chromosomal mapping, cell and
CC   tissue typing, forensic biology); predictive medicine (diagnostic assays,
CC   prognostic assays, monitoring clinical trials, and pharmocogenomics); and
CC   methods of treatment (e.g. therapeutic and prophylactic), especially
CC   disorders characterized by aberrant cell proliferation and/ or
CC   differentiation like cancer or immune associated disorders or gestational
CC   disease. The present sequence represents a SEC10 protein.
XX
SQ   Sequence   464 AA;

  Query Match             26.3%;  Score 1448;  DB 22;  Length 464;
  Best Local Similarity   56.1%;  Pred. No. 3.1e-105;
  Matches  257;  Conservative   73;  Mismatches  122;  Indels    6;  Gaps    6;

Qy     103 MKDQSCKPCAEGRYSLGTGIRFDEWDELPHGFASLSANMELDDSAAES-TGNCTSSKWVP 161
           ||:| |  | || ||||:||:||||||||| ||:::: |:      ::|    | :| |:|
Db       1 MKNQVCSKCGEGTYSLGSGIKFDEWDELPAGFSNIATFMDTVVGPSDSRPDGCNNSSWIP 60

Qy     162 RGDYIAFNTDECTATLMYAVNLKQSGTVNFEYYYPDSSIIFEFFVQNDQCQP-NADDSRW 220
           ||:||  | |:|| :|:|||:||:|| | ||| | |::| ||||:|||||  :    :|
Db      61 RGNYIESNRDDCTVSLIYAVHLKKSGYVFFEYQYVDNNIFFEFFIQNDQCQEMDTTTDKW 120

Qy     221 MKTTEKG-WEFHSVELNRGNNVLYWRTTAFSVWTKVPKPVLVRNIAITGVAYTSECFPCK 279
           :| |: | |  ||| |  | |:||||||   : :|  |||||:|| | ||||||||||||
Db     121 VKLTDNGEWGSHSVMLKSGTNILYWRTTGILMGSKAVKPVLVKNITIEGVAYTSECFPCK 180

Qy     280 PGTYADKQGSSFCKLCPANSYSNKGETSCHQC-DPDKYSEKGSSSCNVRPACTDKDYFYT 338
           |||:::| ||  |::|| |:|| ||   | :| |  ::|||:||| |  || || ||||
Db     181 PGTFSNKPGSFNCQVCPRNTYSEKGAKECIRCKDDSQFSEEGSSECTERPPCTTKDYFQI 240

Qy     339 HTACDANGETQLMYKWAKPKICSEDLEGAVKLPASGVKTHCPPCNPGFFKTNNSTCQPCP 398
           || ||  |:||:|||| :|||| |||  |::|| || |  |||||||:   :|:| |||
Db     241 HTPCDEEGKTQIMYKWIEPKICREDLTDAIRLPPSGEKKDCPPCNPGFYNNGSSSCHPCP 300

Qy     399 YGSYSNGS-DCTRCPAGTEPAVGFEYKWWNTLPTNMETTVLSGINFEYKGMTGWEVAGDH 457
            |::|:|: :|  |||||||:|||||||| || ||:|:  :  | :  || ||||||||
Db     301 PGTFSDGTKECRPCPAGTEPALGFEYKWWNVLPGNMKTSCFNVGNSKCDGMNGWEVAGDH 360

Qy     458 IYTAAGASDNDFMILTLVVPGFRPPQSVMADTENKEVARITFVFETLCSVNCELYFMVGV 517
           | : || ||||::|| | :|||:|| | |      |: ||||||||||| :| ||||| :
Db     361 IQSGAGGSDNDYLILNLHIPGFKPPTS-MTGATGSELGRITFVFETLCSADCVLYFMVDI 419

Qy     518 NSRTNTPVETWKGSKGKQSYTYIIEENTTTSFTWAFQR 555
           | ::   ||:| |:| ||:||:|| :| | :|||   |
Db     420 NRKSTNVVESWGGTKEKQAYTHIIFKNATFTFTWGIPR 457


RESULT 14
AAB48372
ID   AAB48372 standard; Protein; 411 AA.
XX
AC   AAB48372;
XX
DT   20-APR-2001  (first entry)
XX
DE   Human SEC5 protein sequence (clone ID 1795045.0.61).
XX
KW   SECX; cytostatic; gynecological; gene therapy; screening assay; human;
KW   SEC5; chromosomal mapping; forensic biology; cell proliferation; cancer;
KW   cell differentiation; immune associated disorder; gestational disease.
XX
OS   Homo sapiens.
```

XX
PN WO200078802-A2.
XX
PD 28-DEC-2000.
XX
PF 23-JUN-2000; 2000WO-US17328.
XX
PR 23-JUN-1999; 99US-0140584.
PR 20-JUL-1999; 99US-0144722.
PR 16-SEP-1999; 99US-0154520.
PR 22-JUN-2000; 2000US-0604286.
XX
PA (CURA-) CURAGEN CORP.
XX
PI Shimkets RA, Fernandes E, Vernet C, Yang M, Boldog FL;
PI Herrmann JL;
XX
DR WPI; 2001-071385/08.
DR N-PSDB; AAC84886.
XX
PT Polynucleotides encoding SECX proteins useful for treating disease
PT characterized by an aberrant level of cell proliferation and/or
PT differentiation like cancer or immune associated disorders -
XX
PS Claim 1; Fig 6; 132pp; English.
XX
CC The invention relates to human SECX polypeptides and polynucleotides
CC encoding them. The SECX polypeptides can be expressed by standard
CC recombinant methodology. The SECX polypeptides are useful for treating
CC or preventing a SECX-associated disorder. The invention is useful in
CC screening assays; detection assays (e.g. chromosomal mapping, cell and
CC tissue typing, forensic biology); predictive medicine (diagnostic assays,
CC prognostic assays, monitoring clinical trials, and pharmocogenomics); and
CC methods of treatment (e.g. therapeutic and prophylactic), especially
CC disorders characterized by aberrant cell proliferation and/ or
CC differentiation like cancer or immune associated disorders or gestational
CC disease. The present sequence represents a SEC5 protein.
XX
SQ Sequence 411 AA;

Query Match 23.7%; Score 1307.5; DB 22; Length 411;
Best Local Similarity 57.3%; Pred. No. 3e-94;
Matches 231; Conservative 62; Mismatches 105; Indels 5; Gaps 5;

```
Qy    157 SKWVPRGDYIAFNTDECTATLMYAVNLKQSGTVNFEYYYPDSSIIFEFFVQNDQCQP-NA 215
          | |:|||:||  | |:|| :|:|||:||:|| | ||| | |::| ||||:|||||  :
Db      3 SSWIPRGNYIESNRDDCTVSLIYAVHLKKSGYVFFEYQYVDNNIFFEFFIQNDQCQEMDT 62

Qy    216 DDSRWMKTTEKG-WEFHSVELNRGNNVLYWRTTAFSVWTKVPKPVLVRNIAITGVAYTSE 274
            :|:| |: | |  ||| |  | |:|||||   : :|  |||||:|| | |||||||
Db     63 TTDKWVKLTDNGEWGSHSVMLKSGTNILYWRTTGILMGSKAVKPVLVKNITIEGVAYTSE 122

Qy    275 CFPCKPGTYADKQGSSFCKLCPANSYSNKGETSCHQC-DPDKYSEKGSSSCNVRPACTDK 333
          ||||||||:::| ||  |::|| |:|| ||   | :| |  ::||:||| |  || || |
Db    123 CFPCKPGTFSNKPGSFNCQVCPRNTYSEKGAKECIRCKDDSQFSEEGSSECTERPPCTTK 182

Qy    334 DYFYTHTACDANGETQLMYKWAKPKICSEDLEGAVKLPASGVKTHCPPCNPGFFKTNNST 393
          |||  || ||  |:||:|||| :|||| |||  |::|| || |  ||||||||:   :|:
Db    183 DYFQIHTPCDEEGKTQIMYKWIEPKICREDLTDAIRLPPSGEKKDCPPCNPGFYNNGSSS 242

Qy    394 CQPCPYGSYSNGS-DCTRCPAGTEPAVGFEYKWWNTLPTNMETTVLSGINFEYKGMTGWE 452
          | ||| |::|:|: :|  |||||||:|||||||| || ||:|:  :  | :  || |||
Db    243 CHPCPPGTFSDGTKECRPCPAGTEPALGFEYKWWNVLPGNMKTSCFNVGNSKCDGMNGWE 302

Qy    453 VAGDHIYTAAGASDNDFMILTLVVPGFRPPQSVMADTENKEVARITFVFETLCSVNCELY 512
          |||||| : || ||||::|| | :|||:|| | |      |: ||||||||||| :| ||
Db    303 VAGDHIQSGAGGSDNDYLILNLHIPGFKPPTS-MTGATGSELGRITFVFETLCSADCVLY 361

Qy    513 FMVGVNSRTNTPVETWKGSKGKQSYTYIIEENTTTSFTWAFQR 555
          ||| :| ::   ||:| |:| ||:||:|| :| | :|||   |
Db    362 FMVDINRKSTNVVESWGGTKEKQAYTHIIFKNATFTFTWGIPR 404
```

RESULT 15
AAB83852
ID AAB83852 standard; Protein; 209 AA.
XX
AC AAB83852;
XX
DT 23-JUL-2001 (first entry)
XX
DE Amino acid sequence of a human protein expressed in tumour cells.
XX
KW Tumour cell; immunological disease; autoimmune disease; cancer;
KW infection.
XX
OS Homo sapiens.
XX
PN WO200131003-A1.
XX
PD 03-MAY-2001.
XX
PF 30-OCT-2000; 2000WO-FR03032.
XX
PR 29-OCT-1999; 99FR-0013629.
XX
PA (FABR ) FABRE MEDICAMENT SA PIERRE.
XX
PI Delneste Y, Magistrelli G, Jeannin P, Bonnefoy J;
XX
DR WPI; 2001-328651/34.
DR N-PSDB; AAF89776.
XX
PT New nucleic acid, expressed in tumours and lymphoid tissue is useful for
PT identifying agents for treating tumours and autoimmune disease -
XX
PS Claim 10; Page 71-72; 85pp; French.
XX
CC The present sequence represents a human protein expressed in tumour
CC cells. The polynucleotide is useful for screening cDNA/genomic DNA banks
CC and for cloning isolated DNA; identifying mutant forms of the gene that
CC encodes a human protein, where the mutations are associated with
CC abnormal gene expression, or promoters and regulators of the gene,
CC particularly for diagnosis; for recombinant expression of the derived
CC protein; as probes and primers for detection and amplification; and
CC as antisense therapeutics. The tumour expressed protein is useful for
CC raising specific antibodies and to screen agents that modulate its
CC activity, bind to it or interact with it. These agents are potentially
CC useful for treatment or prevention of diseases associated with abnormal
CC expression/activity of the protein, particularly immunological diseases
CC (autoimmune diseases and cancer) or viral, bacterial, fungal or parasitic
CC infections.
XX
SQ Sequence 209 AA;

Query Match 21.2%; Score 1169; DB 22; Length 209;
Best Local Similarity 99.5%; Pred. No. 8.8e-84;
Matches 208; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy    310 QCDPDKYSEKGSSSCNVRPACTDKDYFYTHTACDANGETQLMYKWAKPKICSEDLEGAVK 369
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1 QCDPDKYSEKGSSSCNVRPACTDKDYFYTHTACDANGETQLMYKWAKPKICSEDLEGAVK 60

Qy    370 LPASGVKTHCPPCNPGFFKTNNSTCQPCPYGSYSNGSDCTRCPAGTEPAVGFEYKWWNTL 429
          |||||||||||||||||||||||||||||| ||||||||||||||||||||||||||||||
Db     61 LPASGVKTHCPPCNPGFFKTNNSTCQPCPYGPYSNGSDCTRCPAGTEPAVGFEYKWWNTL 120

Qy    430 PTNMETTVLSGINFEYKGMTGWEVAGDHIYTAAGASDNDFMILTLVVPGFRPPQSVMADT 489
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    121 PTNMETTVLSGINFEYKGMTGWEVAGDHIYTAAGASDNDFMILTLVVPGFRPPQSVMADT 180

Qy    490 ENKEVARITFVFETLCSVNCELYFMVGVN 518
          |||||||||||||||||||||||||||||
Db    181 ENKEVARITFVFETLCSVNCELYFMVGVN 209
```

Search completed: March 12, 2003, 00:12:51
Job time : 58 secs